Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-12, Stock:ABBV, The news for the past five days is as follows:
2018-10-05: NEWS1: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV.NEWS2: AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis.NEWS3: Roche's Hemlibra Receives FDA Approval for Label Expansion.NEWS4: Roche's Hemlibra Receives FDA Approval for Label Expansion.NEWS5: SHAREHOLDER ALERT: PVG OPK USAT TRCO MCHP COCP ABBV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS6: GW Pharmaceuticals: Q3 Performance, Q4 Estimates.NEWS7: AbbVie Inc. Financial Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches of Fiduciary Duty by Officers and Directors.NEWS8: Gilead Announces Positive Data From Ongoing Biktarvy Study.NEWS9: Gilead Announces Positive Data From Ongoing Biktarvy Study.NEWS10: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV.NEWS11: Analyzing Seattle Genetics’ Key Collaborations.
2018-10-08: NEWS1: 3 Top Biotech Stocks to Buy in October.NEWS2: 3 Top Biotech Stocks to Buy in October.NEWS3: 3 Top Biotech Stocks to Buy in October.NEWS4: SHAREHOLDER ALERT: SKX PM USAT MCHP ABBV ALNY MGTI CPB CHGG ADNT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS5: AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis.NEWS6: AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis.NEWS7: AbbVie&apos;s Orilissa Gets Canadian Nod to Treat Endometriosis.NEWS8: AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting.
2018-10-09: NEWS1: Pomerantz Law Firm Announces the Filing of a Class Action against AbbVie Inc. and Certain Officers – ABBV.NEWS2: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of USAT, MCHP, ABBV, ALNY and CPB.
2018-10-10: NEWS1: AbbVie (ABBV) Stock Moves -1.54%: What You Should Know.NEWS2: AbbVie (ABBV) Stock Moves -1.54%: What You Should Know.NEWS3: Neurocrine Inks Deal with Private Biotech to Make CNS Drugs.NEWS4: Neurocrine Inks Deal with Private Biotech to Make CNS Drugs.NEWS5: AbbVie (ABBV) Stock Moves -1.54%: What You Should Know.NEWS6: CLASS ACTION UPDATE for ABBV, ALNY and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS7: IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS8: SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AbbVie Inc. (NYSE: ABBV) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit.NEWS9: J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study.NEWS10: J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study.NEWS11: Ex-Dividend Reminder: AbbVie, ConnectOne Bancorp and Pennymac Mortgage Investment Trust.NEWS12: Ex-Dividend Reminder: AbbVie, ConnectOne Bancorp and Pennymac Mortgage Investment Trust.NEWS13: J&J&apos;s Stelara Succeeds in Phase III Ulcerative Colitis Study.NEWS14: How Novartis’s Sandoz Business Has Been Performing Recently.
2018-10-11: NEWS1: Abbvie settles Humira patent disputes with Novartis unit.NEWS2: CLASS ACTION UPDATE for ABBV, MGTI and SFIX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS3: Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes.NEWS4: Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes.NEWS5: IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS6: AbbVie stock ticks higher as Humira patent dispute with Novartis resolved.NEWS7: Can biotech thrive in a highrise? One developer discovers that it can.NEWS8: AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz.NEWS9: SHAREHOLDER ALERT: TRCO USAT MCHP COCP ABBV ALNY MGTI CHGG ADNT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS10: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for October 12, 2018.NEWS11: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for October 12, 2018.

Answer: Decrease